Will A

Limiting the duration of antibiotic therapy is an attractive stewardship intervention with the potential to improve patient outcomes. However, applying this intervention to the SOT population is complicated by prevailing prescribing cultures and lack of data. #IDtwitter

Thank you @Stanford_ID for this recognition.. Can’t wait to see all the amazing things you’ll do!

Creative combination treatment ideas for this isolate? CF patient s/p lung transplant in 2022. @Willeeuhmm @DHpharmd @jfsisaacs5

@Willeeuhmm @TransplantIDNet @StanfordASP 👋 @Willeeuhmm! Not sure if our peds experience is of interest but our center recs cefazolin x 24 hr post-kidney transplant regardless of deceased or living donor. Donor or recipient cultures preceding may be taken into consideration. Looking forward to hearing other responses!

@StanfordPedsASP @TransplantIDNet @StanfordASP Thank you! That is helpful :)

Question for #TxID #IDTwitter Does your center provide different abx surg ppx recs for kidneys coming from deceased vs living donors? Ex pip tazo for deceased vs cefazolin for living. Also, any difference in duration of abx ppx (eg 48 vs <24 hrs) @TransplantIDNet @StanfordASP

@morelli_md @TBrnaughtTB

@TBrnaughtTB Well I'm more intrigued by what causes an "ASP inbasket trigger?" 👀👀

@DHpharmd @NateShivelyMD @StanfordASP @Stanford_ID Thanks, @DHpharmd! Great to meet you, @NateShivelyMD.

@NateShivelyMD @Willeeuhmm So lucky to be able to experience the genius of @Willeeuhmm every day! @StanfordASP @Stanford_ID 🙌🏼

Next up is Dr. Will Allegria to talk about stewardship in Immunocompromised patients. This is a complicated patient population. #SHEASpring2024 1/

Our @Stanford_ID fellows are all exceptional. Great job, @AlexZimmet! 👏🏽

Congrats, Alex (@AlexZimmet), David (@DHpharmd), Emily (@EmilyMui), Mary Smith, Marty (@MartenHawkins), Will (@Willeeuhmm), and Marisa (@Marisa_Holubar)! More excellent work from our awesome stewardship department headed up by Dr. Marisa Holubar!

Combination Antifungal Therapy for Invasive Mucormycosis in Immunocompromised Hosts: A Single-Center Experience ✅ Just Accepted 🔓 Open Access 🔗 bit.ly/3OTb8OF @DHpharmd @jessicawithID @Pharm_Bean @EmilyMui @StanDeresinski @Marisa_Holubar @Willeeuhmm

🆕️🔥 Single centre cohort study @StanfordASP @bluPharmD @DHpharmd &🌟s* In immunocompromised pts with Invasive Mucormycosis neither upfront nor salvage antifungal combo Rx was associated with a difference in 6 week mortality compared to monotherapy academic.oup.com/ofid/advance-a…

Great session with 🌟panelists. Great to see two of my personal mentors on stage @Marisa_Holubar @Payal_Patel who have helped shape my own career! @IDSAInfo @SIDPharm #IDWeek2023

Nagel Pharmily Reunion @IDWeekmtg! (Missing Marie, Twisha, Farnaz, @Willeeuhmm @NikkiTranID) #IDWeek2023 @MMAbxStew

@MartenHawkins @StanfordASP Next time!

@Willeeuhmm @StanfordASP Sorry 😭😭😭

Bummed we couldn’t get a group pic with everyone but it was great strategic planning day @StanfordASP

@Marisa_Holubar @EmilyMui @DHpharmd @nmedvedevamd

“Race and ethnicity were determined by clinicians and were not self-reported” -Paper published in JAMA Genuinely curious how a clinician would make that determination 🤷🏽‍♂️

@okwalding “Ew”?!

Proud of Brian Lu (@bluPharmD) our PGY2 ID resident on presenting his poster at #MADID2023 on invasive mucormycosis! @Willeeuhmm @Marisa_Holubar @StanDeresinski @jessicawithID @Pharm_Bean @EmilyMui